Document:

EX-10.11

 Exhibit 10.11 

CONFIDENTIAL TREATMENT REQUESTED 

AMENDMENT TO 
 LICENSE
AGREEMENT (1st Amendment) 
 This Amendment to License Agreement, effective August 31, 2007,
is by and among: 
 Angiotech Pharmaceuticals (US), Inc., a corporation organized and existing under the laws of Washington, with principal offices
at North Bend, WA (“Angiotech US”); 
 Angiodevice International GmbH, a corporation organized and existing under the laws of
Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (“Angiodevice”); and 
 Histogenics
Corporation, a corporation organized and existing under the laws of Delaware (formerly under the laws of Massachusetts), with principal offices at 830 Winter Street, 3rd Floor, Waltham, MA 02451 (formerly at 100 Hospital Road, Malden, MA 02148)
(“Histogenics”). 
 WITNESSETH 

WHEREAS, Angiotech Biomaterials Corp (“Biomaterials”), Angiodevice and Histogenics entered into that certain License Agreement effective as
of May 12, 2005 pursuant to which Angiotech licensed to Histogenics the right to use certain domestic and foreign patents, patent applications and know how relating to the manufacture and use of CT3 (the “Agreement”), a copy of which
is attached hereto; 
 WHEREAS, effective as of November 4, 2005, all of the assets of Biomaterials were sold to Angiotech US and
Biomaterials was wound up (“Angiodevice” and “Angiotech US” shall be collectively referred to as “Angiotech”); 

WHEREAS, in connection with such sale of assets, Biomaterials assigned the Agreement to Angiotech US and Angiotech US assumed all rights and
obligations of Biomaterials under the Agreement as if it were the original party thereto; 
 WHEREAS, Angiotech US represents and warrants to
Histogenics that Angiotech US has assumed all rights and obligations of Biomaterials under the Agreement; and, 
 WHEREAS, Angiotech US,
Angiodevice and Histogenics have determined that it is in their best interests to amend certain provisions of the Agreement. 
 NOW,
THEREFORE, in consideration of the mutual promises and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Angiodevice, Angiotech US and Histogenics
(Angiotech US, Angiodevice and Histogenics shall be individually referred to as “Party” and collectively as “Parties”) hereby agree as follows: 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 1. Definitions. Capitalized terms shall have the meanings set forth in the Agreement. The following
defined terms shall be added to Section 1 Definitions of the Agreement in the correct alphabetical order: 
 “Conversion
to Exclusivity” shall have the meaning ascribed to it in Section 3.2(a). 
 “Exclusivity Deadline” shall have
the meaning ascribed to it in Section 3.2(a). 
 “Exclusivity Payment” shall have the meaning ascribed to it in
Section 3.2(a). 
 “Revenue Share Reduction Payment” shall have the meaning ascribed to it in Section 3.2(a). 

2. License Grant. Section 2.1 Grant of the Agreement is hereby amended to include the following additional sentence: 

“Prior to the Exclusivity Deadline as defined in Section 3.2(a) below, and after the Exclusivity Deadline if Histogenics pays
Angiotech the Exclusivity Payment, also as defined in Section 3.2(a) below, Angiotech shall not grant to any other Person any rights to or license under the Licensed Technology to make, have made, use, offer to sell, sell or import any products
containing CT3 for use in the Field in the Territory.” 
 3. Third Party Manufacture. The second sentence of Section 2.4(c)
Manufacturing of the Agreement is hereby changed and replaced with the following: 
 “In the event that Histogenics intends to
have a third party manufacture CT3, Histogenics shall ****.” 
 4. Supply Back. Section 2.4(e)(iv) is hereby added to the Agreement as
follows: 
 (iv) Notwithstanding anything to the contrary in Section 2.4, Angiotech hereby acknowledges and confirms that Histogenics
may sublicense to **** (currently a subsidiary of ****) the right to manufacture CT3 or any components of CT3, including methylated collagen. Further, Angiotech acknowledges that **** is using certain equipment (as more fully described and listed in
Exhibit C (the “****”)) owned by Angiotech in connection therewith, and Angiotech confirms that **** may continue to use such equipment in connection with the manufacture of CT3 or any of its components. Histogenics

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 2 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
hereby agrees to purchase the **** at the agreed to purchase price of ****. 
 5. Supply Back.
Section 2.4(e)(i) of the Agreement is hereby deleted in its entirety and replaced with the following new Section 2.4(e)(i): 

“(i) Histogenics shall use commercially reasonable efforts to supply CT3 to Angiotech at ****, for use only for research and in
preclinical and clinical studies by Angiotech. Histogenics shall not be required to produce any quantities of CT3 for use in commercial products by Angiotech except, (i) where Angiotech has provided Histogenics with at least **** lead time for
delivery of CT3 and, (ii) where the amount of CT3 ordered by Angiotech does not exceed **** of the amount to be produced by Histogenics during that **** period. In the event that **** of the amount of CT3 being produced by Histogenics is not
sufficient to fill an order by Angiotech, Histogenics shall deliver the remaining portions of the order from subsequent production runs. For further clarification, Angiotech shall never be entitled to more than **** of a production run, except at
the sole discretion of Histogenics.” 
 6. Equipment Purchase. A new section, Section 2.4(h) is hereby added to the Agreement as follows:

 (h) Equipment Purchase. Histogenics hereby agrees to purchase for **** from Angiotech the equipment used in the making of CT3
located at ****, that is the property of Angiotech. A list of such equipment is provided in Exhibit C. Histogenics shall be required to pay to Angiotech the **** by September 28, 2007, and upon receipt of such payment in full, all right, title
and interest in and to the **** Equipment shall automatically and without any further action on the part of either Party be sold, assigned, conveyed and transferred to Histogenics, free and clear of all liens and encumbrances of any kind.
Histogenics acknowledges and agrees that Angiotech makes no representations or warranties regarding the **** Equipment, or the accuracy or completeness of Exhibit C, and that Histogenics is purchasing the **** Equipment on an “as is and where
is” basis. 
 7. Revenue Sharing. Section 3.2(a) Revenue Sharing of the Agreement is hereby deleted in its entirety and replaced
with the following new Section 3.2(a): 
 “(a) Revenue Sharing. 

(i) As further consideration for the Histogenics License, within **** after the end of each Calendar Quarter during the Term, Histogenics shall
pay to Angiotech **** of the first **** of Net Sales of Eligible Products and, thereafter, **** of Net Sales of Eligible Products until such time as Histogenics makes the Revenue Share Reduction Payment, as defined below. 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 3 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (ii) At any time prior to the first to occur of, (A) ****, or (B) **** (the
“Exclusivity Deadline”), Histogenics may elect to convert this License to one of exclusivity within the Field by giving notice to Angiotech and paying one million dollars ($1,000,000) to Angiotech (the “Exclusivity Payment”)
within fifteen (15) days of such notice (the “Conversion to Exclusivity”). 
 (iii) If Histogenics exercises the Conversion to
Exclusivity and at such time as Histogenics pays to Angiotech prior to **** an additional two million dollars ($2,000,000) (the “Revenue Share Reduction Payment”), Histogenics shall thereafter be required to pay to Angiotech **** of Net
Sales of those Eligible Products that contain living human cartilage cells and **** of Net Sales of those Eligible Products that do not contain living human cartilage cells. The payments of a percentage of Net Sales of Eligible Products as
determined in this Section 3.2(a) shall be referred to herein as the “Revenue Share”. 
 8. Obligation to Pay Revenue Share.
Section 3.2(b) Obligation to Pay Revenue Share of the Agreement is hereby amended to change the reference to Angiodevice to Angiotech. 
 9.
Diligence Obligations. The last sentence of Section 4.1 Diligence Obligations of the Agreement shall be deleted in its entirety and replaced with the following: 

**** Any such failure to **** will be considered a material breach of this Agreement as that term is used in Section 8.2(a).” 

10. **** 
 11. Publications. Section 5.4
Publications of the Agreement is hereby deleted in its entirety and replaced with the following: 
 “5.4 Publications.
Neither Party will publish or present the results of studies carried out that relate to the performance of CT3 or that contain any Confidential Information of the other Party without (a) such other Party’s prior consent, or
(b) providing such other Party with the opportunity to remove any Confidential Information contained therein.” 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 4 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 12. Accrued Obligations. The second sentence of Section 8.4 Accrued Obligations of the
Agreement is hereby amended by adding the following phrase to the end of the sentence: 
 “...during such **** period.” 

13. Confidentiality. The reference in Section 10.3 Confidentiality of the Agreement to Section 5.6 is hereby changed to
Section 5.1 and Section 5.2. 
 14. Notices. The address for notice to Histogenics in Section 10.9 Notices of the Agreement is
hereby changed to: 
  

			
	If to Histogenics:	  	Histogenics Corporation
		  	830 Winter Street, 3rd Floor
		  	Waltham, MA 02451
		  	Attention: Richard C. Vaillant
		
	With a copy to:	  	Pepper Hamilton LLP
		  	101 Federal Street, Suite 1010
		  	Boston, MA 02110
		  	Attention: ****

 15. License Agreement. Except as specifically otherwise amended as set forth herein, the Agreement shall continue in
full force and effect. 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 5 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 16. Counterparts. This Amendment may be executed in multiple counterparts, each of which shall be
deemed and original, but all of which together shall constitute one and the same instrument. Facsimile signatures of the Parties will have the same effect as original signatures. In making proof of this Amendment, it shall not be necessary to
produce or account for more than one such counterpart. 
 IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed and delivered by the
respective duly authorized officers as of the date set forth above. 
  

													
	ANGIOTECH PHARMACEUTICALS (US), INC.	 		 	 ANGIODEVICE
 INTERNATIONAL
GmbH:

					
	By:	 	 /s/ David Hall
	 		 	By:	 	 /s/ Hans Peter Weber

		 	Name:	 	 David Hall
	 		 		 	Name:	 	 Hans Peter Weber 

		 	Title:	 	 CFO
	 		 		 	Title:	 	 Managing Director

		 	Date:	 	October 4, 2007	 		 		 	Date:	 	26th Sept. 2007
						
		 		 		 		 	By:	 	 /s/ Jürg Dannecker

		 		 		 		 		 	Name:	 	 Jürg Dannecker

		 		 		 		 		 	Title:	 	 Managing Director

		 		 		 		 		 	Date:	 	26/09/2007

  

					
	HISTOGENICS CORPORATION
		
	By:	 	 /s/ Steven Berrota

		 	Name:	 	Steven Berrota
		 	Title:	 	President & CEO
		 	Date:	 	9/11/07

  
 - 6 -EX-10.12

 Exhibit 10.12 

CONFIDENTIAL TREATMENT REQUESTED 

SECOND AMENDMENT 
 TO

 LICENSE AGREEMENT 

THIS SECOND AMENDMENT TO LICENSE AGREEMENT (this “Second Amendment”), effective January 1, 2008, is by and among:

 Angiotech Pharmaceuticals (US), Inc., a corporation organized and existing under the laws of the State of Washington, with
principal offices at North Bend, WA (“Angiotech US”); 
 Angiodevice International GmbH, a corporation organized and
existing under the laws of Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (“Angiodevice”); and 

Histogenics Corporation, a corporation organized and existing under the laws of the State of Delaware (formerly under the laws of
Massachusetts), with principal offices at 830 Winter Street, 3rd Floor, Waltham, MA 02451 (formerly at 100 Hospital Road, Malden, MA 02148) (“Histogenics”). 

WITNESSETH 

WHEREAS, Angiotech Biomaterials Corp. (“Biomaterials”), Angiodevice and Histogenics entered into that certain License
Agreement, effective as of May 12, 2005, pursuant to which Biomaterials and Angiodevice licensed to Histogenics the right to use certain domestic and foreign patents, patent applications and know how relating to the manufacture and use of CT3
(the “Original License Agreement”), a copy of which is attached hereto; 
 WHEREAS, effective as of November 4,
2005, all of the assets of Biomaterials were sold to Angiotech US and Biomaterials was wound up; 
 WHEREAS, in connection with such
sale of assets, Biomaterials assigned the Agreement to Angiotech US and Angiotech US assumed all rights and obligations of Biomaterials under the Original License Agreement as if it were the original party thereto; 

WHEREAS, Angiotech US, Angiodevice and Histogenics entered into that certain Amendment to License Agreement, dated as of
August 31, 2007 (the “First Amendment”), a copy of which is attached hereto (the Original License Agreement, as amended by the First Amendment, shall be referred to herein as the “Agreement”); and 

WHEREAS, Angiotech US, Angiodevice and Histogenics have determined that it is in their best interests to amend certain provisions of
the Agreement. 
 NOW, THEREFORE, in consideration of the mutual promises and agreements set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, Angiodevice, Angiotech US and Histogenics hereby agree as 

  
 - 1 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
follows: 
 1. Amendment. Sub-clause (A) of Section 3.2(a)(ii) of the Agreement is
hereby amended by striking the word “January” and inserting the word “March” in place thereof. 
 2. Miscellaneous 

2.1. Entire Agreement; Confirmation of Agreement. Except as specifically otherwise amended as set forth herein, the Agreement shall
continue in full force and effect. 
 2.2. Counterparts. This Second Amendment may be executed in multiple counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures of the parties hereto will have the same effect as original signatures. In making proof of this Second Amendment, it
shall not be necessary to produce or account for more than one such counterpart. 
 [Signature Page Follows] 

  
 - 2 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 IN WITNESS WHEREOF, the parties have caused this Second Amendment to be executed and
delivered by the respective duly authorized officers as of the date set forth above. 
  

													
	ANGIOTECH PHARMACEUTICALS (US), INC.	 		 	ANGIODEVICE INTERNATIONAL GmbH
					
	By:	 	 /s/ David Hall
	 		 	By:	 	 /s/ Hans Peter Weber

		 	Name:	 	  
	 		 		 	Name:	 	 Hans Peter Weber

		 	Title:	 	Chief Compliance Officer & Senior	 		 		 	Title:	 	 Managing Director

		 		 	Vice President Government &	 		 		 	Date:	 	  

		 		 	Community Relations	 		 		 		 	
		 	Date:	 	 Jan 10, 2008
	 		 		 		 	
		 		 		 		 	By:	 	 /s/ Jürg Dannecker

		 		 		 		 		 	Name:	 	 Jürg Dannecker

		 		 		 		 		 	Title:	 	 Managing Director

		 		 		 		 		 	Date:	 	  

					
	HISTOGENICS CORPORATION	 		 		 		 	
						
	By:	 	  
	 		 		 		 	
		 	Name:	 	  
	 		 		 		 	
		 	Title:	 	  
	 		 		 		 	
		 	Date:	 	  
	 		 		 		 	

  
 - 3 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE
SECURITIES LAWS. THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY
SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 
 RESTATED WARRANT 

to purchase shares of common stock of 

HISTOGENICS CORPORATION 
 Warrant No.
CS-1 
  

			
	Effective Date:	 	July 19, 2006
	Expiration Date:	 	May 11, 2010

 WHEREAS, On May 12, 2005, HISTOGENICS CORPORATION, a corporation organized and existing under the laws of
Massachusetts, with principal offices at 100 Hospital Road, Malden, MA 02148 (the “Massachusetts Corporation”) issued to ANGIODEVICE INTERNATIONAL GmbH, a corporation organized and existing under the laws of Switzerland, with principal
offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (“Angiotech International”), a warrant to purchase **** shares of the Company’s Common Stock (the “Original Warrant”). 

WHEREAS, the Original Warrant was issued pursuant to the License Agreement between the Massachusetts Corporation and the Holder dated as of
May 12, 2005 (the “License Agreement”). 
 WHEREAS, the License Agreement and the Original Warrant provide that upon the sale
of **** of equity securities by the Massachusetts Corporation (the “Financing”), the Original Warrant would be cancelled and replaced with a new warrant of like tenor the right to purchase such additional number of shares of Common Stock,
calculated pursuant to the Original Warrant and the License Agreement. 
 WHEREAS, in connection with the Financing, the Massachusetts
Corporation reincorporated as a Delaware corporation by merging (the “Merger”) the Massachusetts Corporation into a wholly owned Delaware subsidiary, with such subsidiary surviving the Merger (the “Company”). 

WHEREAS, pursuant to the Merger the Company is the successor of the Massachusetts Corporation under the License Agreement and is therefore
issuing this new restated Warrant contemplated by the Original Warrant and the License Agreement. 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 WHEREAS, the Financing has occurred and therefore this Warrant amends and restates the
Original Warrant in its entirety. 
 NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 This certifies that
Angiotech International, or its transferees or assigns (collectively, the “Holder”) for the agreed upon value of and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, shall be entitled
to purchase from the Company, **** fully paid and nonassessable shares of the Company’s Common Stock (the “Common Stock”) for cash at a price of **** per share (the “Exercise Price”) at any time, or from time to time, up to
and including 5:00 p.m. Pacific time on the Expiration Date, upon the surrender to the Company at its principal place of business (or at such other location as the Company may advise the Holder in writing) of this Warrant properly endorsed, a
Subscription Form in substantially the form attached hereto as Exhibit A duly filled in and signed and, as applicable, upon payment in cash or by check of the aggregate Exercise Price for the number of shares for which this Warrant is
being exercised determined in accordance with the provisions hereof, or the surrender of the right to acquire the number of shares of Common Stock determined in accordance with Section 1.2. The Exercise Price and the number of shares of Common
Stock purchasable hereunder are subject to adjustment as provided in Section 3 of this Warrant. 
 This Warrant is subject to the
following terms and conditions: 
 1. EXERCISE; ISSUANCE OF CERTIFICATES;
PAYMENT FOR SHARES. 
 1.1 General. This Warrant is exercisable at the option of the
holder of record hereof at any time, or from time to time, up to the Expiration Date for all or any part of the shares of Common Stock (but not for a fraction of a share), which may be purchased hereunder. The Company agrees that the shares of
Common Stock purchased under this Warrant shall be and are deemed to be issued to the Holder hereof as the record owner of such shares as of the close of business on the date on which this Warrant, properly endorsed, the completed and executed Form
of Subscription and appropriate payment for such shares shall have each been delivered to the Company at its principal place of business. Certificates for the shares of Common Stock so purchased, together with any other securities or property to
which the Holder is entitled upon such exercise, shall be delivered to the Holder by the Company at the Company’s expense within a reasonable time after the rights represented by this Warrant have been so exercised, and in any event, within
five (5) business days of such exercise. In case of a purchase of less than all the shares which may be purchased under this Warrant, the Company shall cancel this Warrant and execute and deliver a new Warrant or Warrants of like tenor for the
balance of the shares purchasable under the Warrant surrendered upon such purchase to the Holder hereof within a reasonable time. Each stock certificate so delivered shall be in such denominations of Common Stock as may be requested by the Holder
hereof. 
 1.2 Net Issue Election. The Holder may elect to receive, without the payment by the Holder of any additional
consideration, shares of Common Stock equal to the value of this 

  
 2 

 
 Common Stock Warrant 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH
RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
Warrant or any portion hereof by the surrender of this Warrant or such portion to the Company, with the net issue election notice annexed hereto duly executed, at the office of the Company.
Thereupon, the Company shall issue to the Holder such number of fully paid and nonassessable shares of Common Stock as is computed using the following formula: 

X = Y (A-B) 

     A 
 where 

 

					
	X	 	=	 	the number of shares of Common Stock to be issued to the Holder pursuant to this Section 1.2.
			
	Y	 	=	 	the number of shares of Common Stock covered by this Warrant in respect of which the net issue election is made pursuant to this Section 1.2.
			
	A	 	=	 	the fair market value of one share of Common Stock, as determined in good faith by the Company’s Board of Directors, as at the time the net issue election is made pursuant to this Section 1.2, which determination shall be
final and binding on the Holder.
			
	B	 	=	 	the Exercise Price in effect under this Warrant at the time the net issue election is made pursuant to this Section 1.2.

 The Board of Directors shall promptly respond in writing to an inquiry by the Holder as to the fair market
value of one share of Common Stock. 
 2. SHARES TO BE FULLY PAID;
RESERVATION OF SHARES. The Company covenants and agrees that all shares of Common Stock which may be issued upon the proper exercise of the rights represented by this Warrant and payment of the
Exercise Price will, upon issuance, be duly authorized, validly issued, fully paid and nonassessable and free from all preemptive rights of any shareholder and free of all taxes, liens and charges with respect to the issue thereof. The Company
further covenants and agrees that, during the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized and reserved, for the purpose of issue or transfer upon exercise of the
subscription rights evidenced by this Warrant, a sufficient number of shares of authorized but unissued Common Stock, or other securities and property, when and as required to provide for the exercise of the rights represented by this Warrant. The
Company will take all such action as may be necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any domestic securities exchange upon
which the Common Stock may be listed; provided, however, that the Company shall not be required to effect a registration under Federal or State securities laws with respect to such exercise. The Company will not take any action which would result in
any adjustment of the Exercise Price (as set forth in Section 3 hereof) if the total number of shares of Common Stock issuable after such action upon exercise of all outstanding warrants, together with all shares of Common Stock then
outstanding and all shares of Common Stock then issuable upon exercise of 

  

			
	  
 Common Stock
Warrant
	  	3

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
all options and upon the conversion of all convertible securities and other equity purchase rights then outstanding, would exceed the total number of shares of Common Stock then authorized by the
Company’s Articles/Certificate of Incorporation (the “Company Charter”). 
 3. ADJUSTMENT OF
EXERCISE PRICE AND NUMBER OF SHARES. The Exercise Price and the number of shares purchasable upon the exercise of this Warrant shall be subject to
adjustment from time to time upon the occurrence of certain events described in this Section 3. Upon each adjustment of the Exercise Price, the Holder of this Warrant shall thereafter be entitled to purchase, at the Exercise Price resulting
from such adjustment, the number of shares obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of shares purchasable pursuant hereto immediately prior to such adjustment, and dividing the product
thereof by the Exercise Price resulting from such adjustment. 
 3.1 Subdivision or Combination of Stock. In case the Company shall
at any time subdivide its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision shall be proportionately reduced, and conversely, in case the outstanding shares of
Common Stock of the Company shall be combined into a smaller number of shares (by reverse stock split or otherwise), the Exercise Price in effect immediately prior to such combination shall be proportionately increased. 

3.2 Dividends in Common Stock, Other Stock, Property, Reclassification. If at any time or from time to time the Holders of Common Stock
(or any shares of stock or other securities at the time receivable upon the exercise of this Warrant) shall have received or become entitled to receive, without payment therefor, 

(a) Common Stock or any shares of stock or other securities which are at any time directly or indirectly convertible into or exchangeable for
Common Stock, or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution, 

(b) any cash paid or payable otherwise than as a cash dividend, or 

(c) Common Stock or additional stock or other securities or property (including cash) by way of spinoff, split-up, reclassification,
combination of shares or similar corporate rearrangement, (other than shares of Common Stock issued as a stock split or adjustments in respect of which shall be covered by the terms of Section 3.1 above), 

then, and in each such case, the Holder hereof shall, upon the exercise of this Warrant, be entitled to receive, in addition to the number of shares of Common
Stock receivable thereupon, and without payment of any additional consideration therefor, the amount of stock and other securities and property (including cash in the cases referred to in clause (b) above and this clause (c)) which such Holder
would hold on the date of such exercise had he been the holder of record of such Common Stock as of the date on which holders of Common Stock received or became entitled to receive such shares or all other additional stock and other securities and
property. 
 3.3 Reorganization, Consolidation, Merger or Sale. If any recapitalization or reorganization of the capital stock of the
Company, or any consolidation or merger of the Company with another corporation, or the sale of all or substantially all of its assets or other 

  

			
	  
 Common Stock
Warrant
	  	4

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
transaction shall be effected in such a way that holders of Common Stock shall be entitled to receive stock, securities, or other assets or property (an “Organic Change”), then, as a
condition of such Organic Change, lawful and adequate provisions shall be made by the Company whereby the Holder hereof shall thereafter have the right to purchase and receive (in lieu of the shares of the Common Stock of the Company immediately
theretofore purchasable and receivable upon the exercise of the rights represented by this Warrant) such shares of stock, securities or other assets or property as may be issued or payable with respect to or in exchange for a number of outstanding
shares of such Common Stock equal to the number of shares of such stock immediately theretofore purchasable and receivable upon the exercise of the rights represented by this Warrant. In the event of any Organic Change, appropriate provision shall
be made by the Company with respect to the rights and interests of the Holder of this Warrant to the end that the provisions hereof (including, without limitation, provisions for adjustments of the Exercise Price and of the number of shares
purchasable and receivable upon the exercise of this Warrant) shall thereafter be applicable, in relation to any shares of stock, securities or assets thereafter deliverable upon the exercise hereof. 

3.4 Certain Events. If any change in the outstanding Common Stock of the Company or any other event occurs as to which the other
provisions of this Section 3 are not strictly applicable or if strictly applicable would not fairly protect the purchase rights of the Holder of the Warrant in accordance with such provisions, then the Board of Directors of the Company shall
make an adjustment in the number and class of shares available under the Warrant, the Exercise Price or the application of such provisions, so as to protect such purchase rights as aforesaid. The adjustment shall be such as will give the Holder of
the Warrant upon exercise for the same aggregate Exercise Price the total number, class and kind of shares as the Holder would have owned had the Warrant been exercised prior to the event and had the Holder continued to hold such shares until after
the event requiring adjustment. 
 3.5 Notices of Change. 

(a) Upon any adjustment in the number or class of shares subject to this Warrant and/or of the Exercise Price, the Company shall give
reasonable written notice thereof to the Holder, setting forth in reasonable detail and certifying the calculation of such adjustment. 

(b) The Company shall give written notice to the Holder at least 10 business days prior to the date on which the Company closes its books or
takes a record for determining rights to receive any dividends or distributions. 
 (c) The Company shall also give written notice to the
Holder at least 10 business days prior to the date on which an Organic Change shall take place. 
 4. ISSUE TAX. The
issuance of certificates for shares of Common Stock upon the exercise of the Warrant shall be made without charge to the Holder of the Warrant for any issue tax (other than any applicable income taxes) in respect thereof; provided, however, that the
Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name other than that of the Holder of the Warrant being exercised. 

  

			
	  
 Common Stock
Warrant
	  	5

 CONFIDENTIAL TREATMENT REQUESTED 

 

 5. CLOSING OF BOOKS. The Company will not unreasonably
close its transfer books in any manner which interferes with the timely exercise of this Warrant. 
 6. NO VOTING
OR DIVIDEND RIGHTS; LIMITATION OF LIABILITY. Nothing contained in this Warrant shall be construed as conferring upon the Holder hereof the right to vote or
to consent or to receive notice as a shareholder of the Company or any other matters or any rights whatsoever as a shareholder of the Company. No dividends or interest shall be payable or accrued in respect of this Warrant or the interest
represented hereby or the shares purchasable hereunder until, and only to the extent that this Warrant shall have been exercised. No provisions hereof, in the absence of affirmative action by the holder to purchase shares of Common Stock, and no
mere enumeration herein of the rights or privileges of the holder hereof, shall give rise to any liability of such Holder for the Exercise Price or as a shareholder of the Company, whether such liability is asserted by the Company or by its
creditors. 
 7. WARRANTS NOT TRANSFERABLE. This Warrant is not transferable, in whole or in part
without the prior written consent of the Company, except as otherwise specifically provided for herein. 
 8. REGISTRATION RIGHTS. The Holder has the
right to cause the Company to register the Common Stock issued upon exercise hereof, under the Securities Act and any blue sky or securities laws of any jurisdictions within the United States at the time and in the manner specified in this
Section 8. 
 8.1 Registrable Securities. As used herein the term “Registrable Security” means the shares of Common
Stock, and any shares issued upon any stock split or stock dividend in respect of such shares of Common Stock; provided, however, that with respect to any particular Registrable Security, such security shall cease to be a Registrable Security when,
as of the date of determination, (i) it has been effectively registered under the Securities Act and disposed of pursuant thereto, (ii) registration under the Securities Act is no longer required for subsequent public distribution of such
security under Rule 144(k) promulgated under the Securities Act or otherwise, or (iii) it is no longer held by the Holder. The term “Registrable Securities” means any and/or all of the securities falling within the foregoing
definition of a “Registrable Security.” In the event of any merger, reorganization, consolidation, recapitalization or other change in corporate structure affecting the Common Stock, such adjustment shall be made in the definition of
“Registrable Security” as is appropriate in order to prevent any dilution or enlargement of the rights granted pursuant to this Section 8. 

8.2 Piggyback Registration. In the event that the Company proposes to prepare and file any new registration statement or post-effective
amendments with the intent of issuing a public offering (including, but not limited to, registration statements relating to secondary offerings of securities of the Company, but excluding registration statements relating to any employee benefit plan
or a corporate reorganization) (for purposes of this Section 8, collectively, the “Registration Statement”), it will give written notice of its intention to do so by certified mail, return receipt requested (“Notice”), at
least thirty (30) business days prior to the filing of each such Registration Statement, to the Holder. Upon the written request of the Holder, made within twenty (20) business days after receipt by the Holder of the Notice, that the
Company include any of the Holder’s Registrable Securities in the proposed Registration Statement, the 

  

			
	  
 Common Stock
Warrant
	  	6

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
Company shall use its best efforts to effect the registration under the Securities Act of the Registrable Securities which it has been so requested to register (“Piggyback
Registration”), at the Company’s sole cost and expense and at no cost or expense to (except as provided in Section 8.3(a) hereof). If the Holder decides not to include all of its Registrable Securities in any Registration Statement
thereafter filed by the Company, the Holder shall nevertheless continue to have the right to include any Common Stock in any subsequent Registration Statement or Registration Statements as may be filed by the Company with respect to offerings of its
securities, all upon the terms and conditions set forth herein. 
 If a Registration Statement under which the Company gives notice under
this Section 8.2 is for an underwritten offering, then the Company shall so advise the Holder. In such event, the right of the Holder’s Common Stock to be included in a registration pursuant to this Section 8.2 shall be conditioned
upon Holder’s participation in such underwriting and the inclusion of Holder’s Common Stock in the underwriting. If Holder proposes to distribute any Common Stock through such underwriting, Holder shall enter into an underwriting agreement
in customary form with the managing underwriter or underwriter(s) selected for such underwriting. 
 Notwithstanding the provisions of this
Section 8.2, the Company shall have the right at any time after it shall have given written notice pursuant to this Section 8.2 (irrespective of whether any written request for inclusion of Registrable Securities shall have already been
made) to elect not to file any such proposed Registration Statement, or to withdraw the same after the filing but prior to the effective date thereof. 

8.3 Covenants of the Company With Respect to Registration. The Company covenants and agrees as follows: 

(a) The Company shall pay all costs, fees and expenses (other than underwriting fees, discounts and nonaccountable expense
allowance applicable to the Registrable Securities and fees and expenses of counsel retained by the Holder) in connection with all Registration Statements including, without limitation, the Company’s legal and accounting fees, printing
expenses, and blue sky fees and expenses. 
 (b) The Company will use its reasonable best efforts to take all necessary
action which may be required in qualifying or registering the Registrable Securities included in the Registration Statement for offering and sale under the securities or blue sky laws of such states as are reasonably requested by the Holder. 

(c) To the fullest extent permitted by law, the Company will indemnify and hold the Holder harmless against any losses, claims,
damages, or liabilities to which it may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon
any of the following statements, omissions or violations (collectively a “Violation”) by the Company: (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, including any
preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements
therein not misleading, 

  

			
	  
 Common Stock
Warrant
	  	7

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act,
the Exchange Act or any state securities law in connection with the offering covered by the Registration Statement; and the Company will reimburse the Holder for any legal or other expenses reasonably incurred by it in connection with investigating
or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity agreement contained in this Section shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such
settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld, conditioned or delayed), nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the
extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished to it expressly for use in connection with such registration by the Holder. 

(d) Promptly after receipt by an indemnified party under this Section of notice of the commencement of any action (including
any governmental action), such indemnified party shall, if a claim in respect thereof is to be made against any indemnifying party under this Section, deliver to the indemnifying party a written notice of the commencement thereof and the
indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the
parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the fees and expenses to be paid by the indemnifying party; and provided further, that if there is more than one indemnified party, the
indemnifying party shall pay for the fees and expenses of one counsel for any and all indemnified parties to be mutually agreed upon by such indemnified parties, unless representation of an indemnified party by the counsel retained by the other
indemnified parties would be inappropriate due to actual or potential differing interests between such indemnified parties. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such
action, if materially prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section, but the omission so to deliver written notice to the indemnifying party will
not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 8. 
 (e) In
the event that the indemnification provided for in this Section 8 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any losses, claims, damages or liabilities referred to herein, the
indemnifying party, in lieu of indemnifying such indemnified party thereunder, shall to the extent permitted by applicable law, contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability
in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the Violation(s) that resulted in such loss, claim, damage or liability, as
well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged

  

			
	  
 Common Stock
Warrant
	  	8

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the
parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. No person or entity guilty of fraudulent misrepresentation (within the meaning of Section 11 of the Securities
Act) shall be entitled to contribution from any person or entity that is not found to have been guilty of such fraudulent misrepresentation. 
 9.
FURTHER REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 

(a) Articles and Bylaws. The Company has made available to Holder true, complete and correct copies of the Company Charter and Bylaws, as
amended, through the date hereof. 
 (b) Due Authority. The execution and delivery by the Company of this Warrant and the performance of all
obligations of the Company hereunder, including the issuance to Holder of the right to acquire the shares of Common Stock, have been duly authorized by all necessary corporate action on the part of the Company, and the Warrant is not inconsistent
with the Company Charter or Bylaws and constitutes a legal, valid and binding agreement of the Company, enforceable in accordance with its terms. 

(c) Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any
state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of its obligations under this Warrant, except for any filing required by applicable federal and state
securities laws, which filing will be effective by the time required thereby. 
 10. REPRESENTATIONS AND
COVENANTS OF THE HOLDER. 
 This Warrant has been entered into by the
Company in reliance upon the following representations and covenants of the Holder: 
 (a) Investment Purpose. The Warrant and the Common
Stock issuable upon exercise of the Warrant will be acquired for investment and not with a view to the sale or distribution of any part thereof, and the Holder has no present intention of selling or engaging in any public distribution of the same
except pursuant to a registration or exemption pursuant to the 1933 Act. 
 (b) Private Issue. The Holder understands (i) that the
Warrant and the Common Stock issuable upon exercise of this Warrant is not registered under the 1933 Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Warrant will be exempt from the
registration and qualifications requirements thereof pursuant to Section 4(2) of the 1933 Act and any applicable state securities laws, and (ii) that the Company’s reliance on such exemption is predicated on the representations set
forth in this Section 10. 

  

			
	  
 Common Stock
Warrant
	  	9

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (c) Disposition of Holders Rights. In no event will the Holder make a disposition of the
Warrant or the Common Stock issuable upon exercise of the Warrant unless and until (i) the Company shall have approved of the proposed disposition, and (ii) if requested by the Company, it shall have furnished the Company with an opinion
of counsel (which counsel may either be inside or outside counsel to the Holder) satisfactory to the Company and its counsel to the effect that (A) appropriate action necessary for compliance with the 1933 Act has been taken, or (B) an
exemption from the registration requirements of the 1933 Act is available. Notwithstanding the foregoing, the restrictions imposed upon the transferability of any of its rights to acquire Common Stock or the Common Stock issuable on the exercise of
such rights do not apply to transfers from the beneficial owner of any of the aforementioned securities to its nominee or from such nominee to its beneficial owner, and shall terminate as to any particular share of Common Stock when (1) such
security shall have been effectively registered under the 1933 Act and sold by the holder thereof in accordance with such registration or (2) such security shall have been sold without registration in compliance with Rule 144 under the 1933
Act, or (3) a letter shall have been issued to the Holder at its request by the staff of the Securities and Exchange Commission or a ruling shall have been issued to the Holder at its request by such Commission stating that no action shall be
recommended by such staff or taken by such Commission, as the case may be, if such security is transferred without registration under the 1933 Act in accordance with the conditions set forth in such letter or ruling and such letter or ruling
specifies that no subsequent restrictions on transfer are required. Whenever the restrictions imposed hereunder shall terminate, as hereinabove provided, the Holder or holder of a share of Common Stock then outstanding as to which such restrictions
have terminated shall be entitled to receive from the Company, without expense to such holder, one or more new certificates for the Warrant or for such shares of Common Stock not bearing any restrictive legend. 

(d) Financial Risk. The Holder has such knowledge and experience in financial and business matters as to be capable of evaluating the merits
and risks of its investment, and has the ability to bear the economic risks of its investment. 
 (e) Risk of No Registration. The Holder
understands that if the Company does not register with the Securities and Exchange Commission pursuant to Section 12 of the 1933 Act, or file reports pursuant to Section 15(d), of the Securities Exchange Act of 1934 (the “1934
Act”), or if a registration statement covering the securities under the 1933 Act is not in effect when it desires to sell (i) the Warrant, or (ii) the Common Stock issuable upon exercise of the Warrant, it may be required to hold such
securities for an indefinite period. The Holder also understands that any sale of the Warrant or the Common Stock issuable upon exercise of the Warrant which might be made by it in reliance upon Rule 144 under the 1933 Act may be made only in
accordance with the terms and conditions of that Rule. 
 (f) Accredited Investor. Holder is an “accredited investor” within the
meaning of Rule 501 of Regulation D under the 1933 Act, as presently in effect. 
 11. MODIFICATION AND
WAIVER. This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the same is sought. 

  

			
	  
 Common Stock
Warrant
	  	10

 CONFIDENTIAL TREATMENT REQUESTED 

 

 12. NOTICES. Any notice, request or other document required or permitted to be given or
delivered to the holder hereof or the Company shall be delivered or shall be sent by an established overnight service provider (e.g., Federal Express), or registered or certified mail, postage prepaid, to each such holder at its address as shown on
the books of the Company or to the Company at the address indicated therefor in the first paragraph of this Warrant or such other address as either may from time to time provide to the other in accordance with this Section. 

13. BINDING EFFECT ON SUCCESSORS. This Warrant shall be binding upon any corporation
succeeding the Company by merger, consolidation or acquisition of all or substantially all of the Company’s assets. All of the obligations of the Company relating to the Common Stock issuable upon the exercise of this Warrant shall survive the
exercise and termination of this Warrant. All of the covenants and agreements of the Company shall inure to the benefit of the successors and assigns of the holder hereof. 

14. DESCRIPTIVE HEADINGS AND GOVERNING LAW. The description headings of the
several sections and paragraphs of this Warrant are inserted for convenience only and do not constitute a part of this Warrant. This Warrant shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the
laws of the State of Delaware, without giving effect to principles of conflicts of laws. 
 15. LOST WARRANTS. The
Company represents and warrants to the Holder hereof that upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction, or mutilation of this Warrant and, in the case of any such loss, theft or destruction, upon
receipt of an indemnity reasonably satisfactory to the Company, or in the case of any such mutilation upon surrender and cancellation of such Warrant, the Company, at its expense, will make and deliver a new Warrant, of like tenor, in lieu of the
lost, stolen, destroyed or mutilated Warrant. 
 16. FRACTIONAL SHARES. No fractional shares shall be issued upon
exercise of this Warrant. The Company shall, in lieu of issuing any fractional share, pay the holder entitled to such fraction a sum in cash equal to such fraction multiplied by the then effective Exercise Price. 

17. ORIGINAL WARRANT CANCELLED. The Original Warrant is hereby replaced in its entirety by this Warrant,
and the Original Warrant shall be null and of no force and effect. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  

			
	  
 Common Stock
Warrant
	  	11

 CONFIDENTIAL TREATMENT REQUESTED 

 

 IN WITNESS WHEREOF, the Company and the Holder have caused this Warrant to be duly executed
by its officers, thereunto duly authorized. 
  

							
	Dated:	 	January 4, 2008	 	HISTOGENICS CORPORATION
				
		 		 	By:	 	 /s/ Steven Bernitz

	(Corporate Seal)	 	Name:	 	Steven Bernitz
		 		 	Title:	 	President & CEO
			
	Dated:	 	January 16, 2008	 	ANGIODEVICE INTERNATIONAL GmbH
				
		 		 	By:	 	 /s/ Hans Peter Weber

	(Corporate Seal)	 	Name:	 	Hans Peter Weber
		 		 	Title:	 	Managing Director
				
		 		 	By:	 	 /s/ Jürg Dannecker

		 		 	Name:	 	Jürg Dannecker
		 		 	Title:	 	Managing Director

  

			
	  
 Common Stock
Warrant
	  	12

 CONFIDENTIAL TREATMENT REQUESTED 

 

 EXHIBIT A 

Subscription Form 
  

									
	To:	 	  
	 		  	Date:	 	  

 The undersigned hereby subscribes for
                 shares of Common Stock covered by this Warrant. The certificate(s) for such shares shall be issued in the name of the undersigned or as otherwise
indicated below: 
  

			
	  

	Signature
		
	Name:	 	  

	Address:	 	  

		 	  

		 	  

 [OR] 

Net Issue Election Notice 
  

									
	To:	 	  
	 		 	Date:	 	  

 The undersigned hereby elects under Section 1.2 to surrender the right to purchase
                 shares of Common Stock pursuant to this Warrant. The certificate(s) for the shares issuable upon such net issue election shall be issued in the name of
the undersigned or as otherwise indicated below. 
  

			
	  

	Signature
		
	Name:	 	  

	Address:	 	  

		 	  

		 	  

  

			
	  
 Common Stock
Warrant
	  	13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]